TLR7 and cancer: Many TLR agonists are in trial as adjuvants for cancer vaccines, like the TLR3 agonist: polyinosinic–polycytidylic acid with polylysine and carboxymethylcellulose (Poly-ICLC), TLR4 agonist: monophosphoryl lipid A (MPLA), TLR7 agonist: imiquimod, TLR7 and TLR8 agonist: resiquimod, and TLR9 agonist: CpG oligodeoxynucleotide (CpG) [76, 91, 92].